---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023202"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:36:26.232696+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Xenon Q3 net loss $37.2M; launches XEN1101 Phase 3 epilepsy program

## Summary
- Revenue $0.1M vs $8.1M YoY; no Neurocrine milestone in Q3 2022.
- Cash $752.2M as of Sep 30, 2022; expected runway into 2026.
- XEN1101 Phase 3 trials X-TOLE2, X-TOLE3 (FOS) and X-ACKT (PGTCS) initiated.
- X-NOVA MDD Phase 2 topline data expected Q3 2023.
- R&D expenses $29.4M, up 56% YoY, driven by XEN1101 program.

## SEC filing metadata
- accession: 0000950170-22-023202
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017022023202/0000950170-22-023202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017022023202/xene-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023202
- JSON: https://secwatch.observer/filing/0000950170-22-023202.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023202.txt

## Key facts
- Earnings Releases
  Xenon Pharmaceuticals Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 8, 2022, Xenon Pharmaceuticals Inc. (the “Company”) announced via press release the Company’s financial results for the six and nine months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000095017022023202/0000950170-22-023202-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.